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ObesityWe are facing a revival of the strategy to counteract obesity and associated metabolic disorders by inducing
thermogenesis mediated by mitochondrial uncoupling protein-1 (UCP1). Thus, the main focus is on the adap-
tive non-shivering thermogenesis occurring both in the typical depots of brown adipose tissue (BAT) and in
UCP1-containing cells that could be induced in white adipose tissue (WAT). Because contribution of WAT to
resting metabolic rate is relatively small, the possibility to reduce adiposity by enhancing energy expenditure
in classical white adipocytes is largely neglected. However, several pieces of evidence support a notion that
induction of energy expenditure based on oxidation of fatty acids (FA) in WAT may be beneﬁcial for health,
namely: (i) studies in both humans and rodents document negative association between oxidative capacity
of mitochondria in WAT and obesity; (ii) pharmacological activation of AMPK in rats as well as
cold-acclimation of UCP1-ablatedmice results in obesity resistance associatedwith increased oxidative capacity
in WAT; and (iii) combined intervention using long-chain n-3 polyunsaturated FA (omega 3) and mild calorie
restriction exerted synergism in the prevention of obesity in mice fed a high-fat diet; this was associated with
strong hypolipidemic and insulin-sensitizing effects, as well as prevention of inﬂammation, and synergistic in-
duction of mitochondrial oxidative phosphorylation (OXPHOS) and FA oxidation, speciﬁcally in epididymal
WAT. Importantly, these changes occurred without induction of UCP1 and suggested the involvement of:
(i) futile substrate cycle in white adipocytes, which is based on lipolysis of intracellular triacylglycerols and
re-esteriﬁcation of FA, in associationwith the induction ofmitochondrial OXPHOS capacity, β-oxidation, and en-
ergy expenditure; (ii) endogenous lipid mediators (namely endocannabinoids, eicosanoids, prostanoids,
resolvins, and protectins) and their cognate receptors; and (iii) AMP-activated protein kinase in WAT. Quanti-
tatively, the strong induction of FA oxidation inWAT in response to the combined intervention is similar to that
observed in the transgenic mice rendered resistant to obesity by ectopic expression of UCP1 inWAT. The induc-
tion of UCP1-independent FA oxidation and energy expenditure in WAT in response to the above physiological
stimuli could underlie the amelioration of obesity and low-grade WAT inﬂammation, and it could reduce the
release of FA from adipose tissue and counteract harmful consequences of lipid accumulation in other tissues.
In this respect, new combination treatments may be designed using naturally occurring micronutrients
(e.g. omega 3), reduced calorie intake or pharmaceuticals, exerting synergism in the induction of the mitochon-
drial OXPHOS capacity and stimulation of lipid catabolism in white adipocytes, and improving metabolic ﬂexi-
bility of WAT. The role of mutual interactions between adipocytes and immune cells contained inWAT in tissue
metabolism should be better characterised. This article is part of a Special Issue entitled Brown and White Fat:
From Signaling to Disease.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.AMP-activated protein kinase; aP2-Ucp1 mice, transgenic mice expressing UCP1 gene from the aP2 gene promoter; AA,
AT, brown adipose tissue; BCAA, branched-chain amino acids; CB1, cannabinoid type-1 receptor; CR, calorie restriction;
; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FAT/CD36, fatty acid translocase/CD36; FA, fatty acids; FAS,
1; HF, high-fat; HSL, hormone-sensitive lipase; LPS, lipopolysaccharide; omega 3, long-chain n-3 polyunsaturated fatty
hemoattractant protein-1; OXPHOS, oxidative phosphorylation; PC, pyruvate carboxylase; PDK4, pyruvate dehydrogenase
e; PD1, protectin D1; PGC-1, the PPARγ coactivator 1; PPAR, peroxisome proliferator-activated receptor; SIRT1,
rol regulatory element-binding protein-1c; TAG, triacylglycerols; TAG/FA cycle, futile substrate cycle based on lipolysis
fatty acids; TZD, thiazolidinedione; UCP1, mitochondrial uncoupling protein 1; WAT, white adipose tissue; 15d-PGJ2,
and White Fat: From Signaling to Disease.
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cally relevant tissues in the body, is essential for storing metabolic
energy, and through its endocrine functions, it is also involved in the
regulation of glucose as well as energy homeostasis. WAT has also a
major role in the control of systemic fatty acids' (FA) levels. According-
ly, both hypertrophy and atrophy [1] of WAT are associated with
lipotoxic damage of insulin signalling in other tissues. The key role of
WAT in glucose homeostasis [2,3] is supported by the recent experi-
mental evidence of anti-diabetic effects of WAT-speciﬁc up-regulation
of peroxisome proliferator-activated receptor-γ (PPARγ; [4]). Con-
cerning energy homeostasis, the role of WAT metabolism is usually
neglected. However, it is not insigniﬁcant. Thus, the contribution of
WAT to resting metabolic rate in lean human subjects is close to 5%
and it doubles in obesity (reviewed in [5]), while in adult mice reared
at 20 °C the total oxidative capacity of WAT represents ~30–50% of that
in brown adipose tissue (BAT; [6]).
In both humans [7] and rodents [8], oxygen consumption in WAT
cells declines with age and it is negatively correlated with obesity in
humans [7]. Decreased white fat cell thermogenesis in obese humans
was also found using direct microcalorimetry [5]. Accordingly,
mitochondrial content in WAT is relatively low in genetically obese
and insulin-resistant mice [9–12]. Moreover, in monozygotic twins dis-
cordant for obesity, copy number of mitochondrial DNA in subcutane-
ous WAT was reduced by 47% in obese co-twins, in association with
reduced expression of the genes for mitochondrial proteins [13]. In
turn, induction of mitochondria and activation of FA oxidation,
speciﬁcally in WAT, was observed under the conditions promoting
loss of adiposity (see Section 2.4). Very recently, it has been reported
[14] that systemic nonselective β-adrenergic stimulation in humans
that increases energy expenditure to the same extent as cold exposure
does not activate brown adipose tissue (BAT; see below), and could be
explained only in part by the activation of muscle non-shivering
thermogenesis (for review on muscle thermogenesis, see [15–17]).
These data support the notion that also adrenergically-stimulated
energy expenditure in WAT may, though to a relatively small extent,
inﬂuence total energy balance (see also [16] and Section 2.3).
In contrast to energy expenditure inWAT, major role of mitochon-
drial uncoupling protein-1 (UCP1) in BAT with respect to cold- and
diet-induced adrenergically regulated thermogenesis is well appreci-
ated [18–20], although examination of several older studies [15,21]
casts some doubts on the unique role of the UCP1-mediated thermo-
genesis. As described in other articles of this issue, recent discovery of
functional BAT in adult humans [22] has led to a revival of the strate-
gy [23–25] to counteract obesity and associated metabolic disorders
by inducing UCP1-mediated thermogenesis. In rodents, the existence
of several fat cell lineages was uncovered, which underlie the differ-
entiation of precursor cells into: (i) classical multilocular brown
adipocytes, which are closely related to myocytes, and which are re-
sponsible for the bulk of the adaptive UCP1-mediated thermogenesis;
(ii) classical unilocular white adipocytes lacking UCP1, which are fully
competent for ATP synthesis by oxidative phosphorylation (OXPHOS;
[13,26,27]); and (iii) brite adipocytes [28,29] named also beige cells
(reviewed in [30]). The last cell type is of special interest, since
these cells are interspersed in some depots of WAT, they show high
inducibility of the UCP1-linked thermogenic programme, and their
abundance correlates negatively with the propensity to obesity
while being under genetic control [31]. Besides the sympathetic stim-
ulation, synthetic ligands of PPARγ (reviewed in [10,32,33]), as well
as several hormonal factors could induce brite cells in rodents ([34–
38]; see Section 3.1). However, in spite of the fact that markers
discriminating BAT from brite cells have been identiﬁed in rodents
[28,30,38,39], the existence of brite cells in humans remains to
be unequivocally established [30,40], and typical white adipocyte
markers also remain to be deﬁned. In fact, inducibility of at leastsome of the UCP1-containing cells in WAT depots probably reﬂects
transdifferentiation of white adipocytes [41], bringing another level
of complexity to the identiﬁcation of markers characteristic of cell lin-
eages engaged in adipose tissue plasticity.
Energy-dissipating function of UCP1 depends on its protonophoric
activity in the inner mitochondrial membrane, which is activated by
FA in response to β-adrenergic stimulation and allows for a full
unmasking of mitochondrial oxidative capacity without concomitant
synthesis of ATP (for review, see [42]). In fact, the content of mitochon-
drial ATP synthase in classical brown adipocytes is extremely low
[43,44], and this feature is observed already at the time of perinatal re-
cruitment of BAT thermogenesis both in rodents [45,46] and humans
[47]. Adrenergic stimulation of BAT not only activates UCP1-mediated
proton leak but also leads to complex metabolic adaptations (for re-
views onBATmetabolism see [20]), includingmitochondrial biogenesis,
aimed at increasing fuel supply and oxidation. Thus, lipolysis of intracel-
lular triacylglycerols (TAG) stores is accelerated and the uptake of FA
derived from blood-born lipoproteins is increased due to the action of
lipoprotein lipase (LPL) that is rapidly recruited during cold exposure
[48]. Although glucose is not a major substrate for BAT thermogenesis,
glucose utilisation by activated BAT increases dramatically [49] as
does lactate production. Glycolysis supplies ATP when its production
via OXPHOS is attenuated, and also makes pyruvate available for the
synthesis of oxaloacetate, the condensing partner for acetyl-CoA formed
from β-oxidation of FA, thus ensuring a continuous supply of citric acid
cycle intermediates (anaplerosis; see Section 2.4 and [50]). High
expression of the muscle type carnitine palmitoyl transferase-1
(CPT1; [51]) allows for rapid β-oxidation of FA [52], while high activity
of mitochondrial glycerol-3-phosphate dehydrogenase supports TAG
synthesis and controls cytoplasmic NADH levels [53]. Longer exposure
to cold (days) leads to increased lipogenesis, which is necessary for
sustained thermogenesis. Triiodothyronine locally produced from
thyroxine in brown adipocytes [54] ampliﬁes adrenergic stimulation
of UCP1 gene transcription [55], helps to ensure an optimal balance
between lipolysis and lipogenesis [54], and contributes to systemic
triiodothyronine levels [56].
Here, reﬂecting the well accepted potential of UCP1-mediated ther-
mogenesis to reduce obesity, we provide a complementary information
on adipose tissue biology, while focusing on: (i) the possibility to
reduce body fat stores by inducing energy expenditure in white adipo-
cytes based on a futile substrate cycle [57], namely lipolysis of intracel-
lular triacylglycerols and FA re-esteriﬁcation (TAG/FA cycle; [5,58,59]),
in association with the induction of mitochondrial OXPHOS capacity
and β-oxidation; (ii) the role of local mediators in WAT in the regula-
tion of adipocyte metabolism; (iii) the comparison of local/systemic
metabolic effects of TAG/FA cycle vs. mitochondrial uncoupling in
white adipocytes; and (iv) possible interventions, which could
counteract obesity while stimulating activity of TAG/FA cycle, inducing
capacity ofmitochondrial OXPHOS and enhancing FA oxidation inwhite
adipocytes. We provide a concept, that white adipocyte endowed with
high capacity of mitochondrial OXPHOS represents a metabolically
ﬂexible healthy adipocyte.
2. Physiology of mitochondria in white adipocytes
In white adipocytes, similarly as in most other cells, mitochondria
represent the main site of ATP production. Fully coupled mitochondria
could be isolated from adipocytes liberated by the use of collagenase
from epididymal WAT of rats [26], and OXPHOS activity could be also
demonstrated using respirometry in isolated digitonin-permeabilized
murine white adipocytes [27]. Especially in fully differentiated white
adipocytes, mitochondria must generate sufﬁcient ATP to support
various energy-consuming processes (see Sections 2.2 and 2.3). They
are located in the thin cytoplasmic rim of the cells, and they show
similar morphology as in other tissues [60]. Mitochondrial content of
mature white adipocytes is several-fold higher as compared with
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location of fat depots. Thus, in rodents, gonadal adipocytes contain
more mitochondria and have higher oxidative capacity together with
higher content of OXPHOS proteins as compared with adipocytes in
subcutaneous (inguinal) depot [62,63]. Similarly, in obese humans,
mitochondrial DNA (mtDNA) copy number per mg tissue is higher in
visceral than in abdominal subcutaneous WAT [64]. Although mito-
chondrial respiration normalized to cell number or mtDNA is lower
in visceral WAT compared to subcutaneous WAT due to smaller adipo-
cytes in the former fat depot, the visceral fat is bioenergetically more
active and more sensitive to substrates of electron transport chain
than the subcutaneous WAT [64].
It should be stressed that the interpretation of the above data
regarding mitochondrial content is not straightforward. Because of
the complex nature of mitochondria and their biogenesis, multiple
parameters need to be analysed in order to assess mitochondrial con-
tent or activity in WAT. The preferred methods of ours are: (i) trans-
mission electronmicroscopy (e.g. described in [65]); (ii) evaluation of
activity of cytochrome c oxidase and cytochrome b content in crude
membrane fraction (e.g. used in [27]); (iii) quantiﬁcation of selected
mitochondrial proteins by immunoblotting (e.g. described in [66]);
and (iv) measurement of mitochondrial respiration using high-
resolution respirometry in digitonin-permeabilized adipocytes [27].
Moreover, mtDNA quantiﬁcation is frequently used as a marker of mi-
tochondrial content and activity, although each mitochondrion may
contain 2–10 copies of mtDNA. The direct relationship between the
cychrome c oxidase activity and the mtDNA was found in WAT [62]
and in skeletal muscle but not in the liver and other tissues [67].2.1. Control of mitochondrial biogenesis in adipose tissue
In adipocytes, various properties of mitochondria including the
biogenesis, content and speciﬁc composition are controlled at different
levels. At the transcriptional level, this control involves the key
adipogenic transcription factor, PPARγ [68–70], which is predominant-
ly expressed in adipose tissue (namely the PPARγ2 isoform), especially
in mature adipocytes [61,71], and in immune cells [72]. However, the
dynamic control of biogenesis and respiratory function of mitochondria
depends in large on the PPARγ coactivator 1 (PGC-1) family of tran-
scriptional regulators, consisting of PGC-1α, PGC-1β and PGC-1 related
coactivator (PRC; reviewed in [73]). These coactivators target multiple
transcription factors including nuclear respiratory factor 1 (NRF-1) and
oestrogen-related receptor α, while coordinately inducing mitochon-
drial biogenesis in all metabolically relevant tissues (reviewed in
[73,74]). In addition, (i) PGC-1α interacts with either PPARα [75] or
farnesoid X receptor [76] to increase mitochondrial β-oxidation; and
(ii) the interaction of PGC-1αwith PPARγ is required for the induction
of UCP1-mediated thermogenesis in both brown adipocytes and brite
cells in response to various signals including thiazolidinedione (TZD)
antidiabetic drugs [32,33,77], and ﬁbroblast growth factor-21 (FGF21;
Ref. [34,36]). Importantly, the induction of UCP1-mediated thermogen-
esis by TZD also requires PPARα [78] as well as the presence and
accumulation of PRMD16 protein [32], the marker of both brown and
brite adipocytes, which is absent in white adipocytes (reviewed in
[28,32]). In contrast to the role of PGC-1α in the recruitment of
UCP1-mediated thermogenesis, PGC-1β plays a dominant role in the
control of general mitochondrial gene expression in white adipocytes
[33]. Accordingly, the expression of PGC-1β but not PGC-1α increased
along with the in vitro differentiation of preadipocytes isolated from
subcutaneousWAT of the rat [79]. Also in the liver and skeletal muscle,
PGC-1β was required for normal expression of genes encoding mito-
chondrial proteins, including OXPHOS components [80]. PPARα is the
main transcriptional regulator of the lipid oxidation pathway [81].
Activation of PPARs by endogenous ligands, which are generated dur-
ing lipolysis of TAG in adipocyte, contributes to the induction ofmitochondrial biogenesis and lipid catabolism in response to lipolytic
signals (see Section 2.3).
Reﬂecting the indispensable roles of PPARγ and PGC-1 family mem-
bers in adipocytes, the activity of these factors is modulated by several
mechanisms, depending also on the metabolic status. Thus, PPARγ ac-
tivity is regulated by classical agonists—various FA and their metabo-
lites, TZD drugs as well as by non-TZD agonists, which all bind to
PPARγ and could induce its conformational change (reviewed in
[68,82,83]). Furthermore, PPARγ activity is modulated by CDK5-
mediated phosphorylation at serine 273 in response to obesity-linked
pro-inﬂammatory signals, which prevents the expression of a set of
PPARγ targets with anti-obesity effects. Agonist binding to PPARγ
interferes with serine 273 phosphorylation [84]. Association of PPARγ
with CDK5 is facilitated by nuclear receptor corepressor (NCoR),
leading to PPARγ phosphorylation and inactivation [85]. These
ﬁndings: (i) triggered a search for non-agonist PPARγ ligands blocking
the serine 273 phosphorylation, which could elicit antidiabetic action
(including the induction of adiponectin gene expression) without
having side effects of the TZD therapy [86], and (ii) partially elucidat-
ed the link between low-grade WAT inﬂammation in obesity and in-
sulin resistance [87–89]. PPARγ activity is also repressed by
phosphorylation at serine 112, as well as by sumoylation at lysine
107, which is, in turn prevented by FGF21 (reviewed in [90,91]). In
mice, FGF21 helps to recruit UCP1-mediated thermogenesis (see
Section 1 and [34,36]), while PPARγ-FGF21 interaction in white adi-
pocytes is required for the whole-body antidiabetic effects of TZD
(see Section 2.5 and [90]). Importantly, the activation of both
PPARα and PPARγ also results in potent anti-inﬂammatory effects,
which aremediated bymultiplemechanisms, including transrepression
of transcription of inﬂammatory genes (reviewed in [92]; see Sections 2.5
and 4).
The activity of PGC-1 family members is also regulated by
post-translational modiﬁcation elicited by intracellular sensors of
energy status such as AMP-activated protein kinase (AMPK) and
NAD+-dependent deacetylase sirtuin1 (SIRT1; reviewed in [73]).
AMPK is a heteromeric protein, with a dominant expression of the
α1-subunit isoform in WAT. AMPK activation aims to suppress ATP-
consuming processes (such as lipogenesis; see Section 2.2) and stim-
ulate processes leading to the generation of ATP (e.g. β-oxidation,
mitochondrial biogenesis, and glucose uptake; reviewed in [93]),
while, in analogy with its role in heart [94], it could probably also
stimulate uptake of FA by increasing LPL activity in adipocytes. More-
over, by a complex mechanism, AMPK modulates lipolysis of TAG in
adipocytes (see Section 2.3).
SIRT1 closely interacts with AMPK [73,95], and by deacetylating
multiple lysine residues in PGC-1α and NF-κB, it promotes lipid ca-
tabolism and counteracts WAT inﬂammation (see Section 2.4 and
[96,97]). The stimulation of mitochondrial biogenesis in response to
AMPK activation probably depends on the phosphorylation of PGC-1
factors on speciﬁc serine and threonine residues by NO- and p38
MAPK-related mechanisms, although this mechanism remains some-
how controversial (compare [77] and [98]). Furthermore, it is known
that AMPK signalling in white adipocytes is activated by leptin and
adiponectin [99]. In contrast, mitochondrial biogenesis is down-
regulated by endocannabinoids that decrease AMPK activity [98]
through G-protein-coupled cannabinoid type-1 (CB1) receptor in
WAT [100]. By this mechanism, elevated endocannabinoid tonus in
obesity may interfere with mitochondrial biogenesis [98,101] and
deteriorate the ability of mitochondria to augment oxidative capacity
in face of increased lipid supply (see Section 2.4).
2.2. Major role of mitochondria in white adipocytes
Proper functioning of mitochondria in white adipocytes is essential
for metabolism of these cells as well as for the role ofWAT in thewhole
organism. In fact, even adipocyte differentiation and maturation may
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[102], and mitochondrial production of ROS maybe a causal factor in
promoting adipocyte differentiation [103]. In mature white adipocytes,
mitochondrial ATP synthesis is essential for major metabolic pathways,
i.e. lipolysis, de novo FA synthesis, TAG synthesis, glyceroneogenesis,
and FA re-esteriﬁcation.
WAT is an important site of de novo FA synthesis from glucose,
mainly in rodents, however, even in humans WAT may account for
up to 40% of whole-body lipogenesis [104]. The key transcription
factor regulating lipogenic gene expression and thus lipid synthesis
is sterol regulatory element-binding protein-1c (SREBP-1c), and the
important enzymes are fatty acid synthase (FAS) and acetyl-CoA
carboxylase (ACC). ACC is regulated by AMPK (see Section 2.1) through
phosphorylation, which suppresses formation of malonyl-CoA, while
promoting FA oxidation in mitochondria, reﬂecting the release of
malonyl-CoA-mediated inhibition of CPT1 (reviewed in [105]).
Furthermore, stearoyl-CoA desaturase 1 (SCD1) catalyses the synthesis
of monounsaturated fatty acids used to build up TAG, while it also con-
trols lipid partitioning between lipogenesis and FA oxidation [106]. In
this respect, mitochondrial ATP production is required for lipogenesis,
both for de novo FA synthesis as well as for esteriﬁcation of FA.
Thus, the formation of acetyl-CoA for FA synthesis depends on the
cleavage of citrate exported from mitochondria into cytosol, where it
is cleaved by ATP-citrate lyase to generate acetyl-CoA and oxalacetate.
Cytosolic oxalacetate is reduced to malate by NADH, and the malate is
subsequently decarboxylated to pyruvate in a reaction that is catalysed
by malic enzyme and that also generates NADPH to be used during the
synthesis of FA. Pyruvate returns to the mitochondrion, where it can be
converted to oxalacetate in a reaction that requires ATP and is
catalysed by pyruvate carboxylase (PC). This enzyme is a key compo-
nent of the ‘pyruvate cycle’ [107–109] and its activity is about 3-fold
higher in WAT than in the liver (reviewed in [110]), while it is also in-
dispensable for the thermogenic function of BAT ([50]; see above).
Depending on the activity of citric acid cycle, oxalacetate generated
by the action of PC can either enter the cycle to increase its activity
and regenerate citrate or enter the pathway of gluconeogenesis (in
the liver) or glyceroneogenesis (in WAT).
TAG production requires a continuous supply of glycerol-3-
phosphate to esterify FA. Glycerol-3-phosphate can be formed from:
(i) glucose via glycolytic pathway; (ii) glycerol, which is converted to
glycerol-3-phosphate by glycerol kinase; and (iii) precursors other
than glucose and glycerol (such as pyruvate, lactate and amino acids),
by glyceroneogenesis, which forms phosphoenolpyruvate via the
mitochondrial dicarboxylic shuttle and subsequently produces
glycerol-3-phosphate by a partial reversion of glycolysis. While glycerol
kinase is essential for glycerol-3-phosphate formation in BAT [111],
glyceroneogenesis is the dominant pathway for TAG-glycerol synthesis
in WAT ([112]; see Section 2.5). The key enzyme of this metabolic pro-
cess is the cytosolic isoform of phosphoenolpyruvate carboxykinase
(PEPCK), which catalyses decarboxylation of oxaloacetate to form
phosphoenolpyruvate. Another important player in the process
of glyceroneogenesis is mitochondrial pyruvate dehydrogenase that
functions as a metabolic switch between glucose and FA utilisation. Its
inhibition by pyruvate dehydrogenase kinase 4 (PDK4) enables pyru-
vate to be used for glyceroneogenesis when the supply of glucose is
low [113].
2.3. TAG/FA cycle in white adipocytes leads to energy expenditure
Lipolysis of TAG in white adipocytes is associated with re-
esteriﬁcation of a part (30–90% at basal state, and 10–20% at stimulated
state) of lipolyzed FA back into adipose TAG, i.e. futile TAG/FA cycling
([5,58,59,114,115]; reviewed in [116–119]). As for the ﬁrst time
suggested by Newsholme and Crabtree (see Ref. [120]), substrate cycles
could provide a mechanism of variable sensitivity for controlling the
ﬂux through a metabolic pathway (see [121]). Also in WAT, anextensive rate of futile FA recycling probably allows for a ﬁne and fast
tuning of these opposite metabolic ﬂuxes in response to metabolic de-
mands [122,123], and it is essential for buffering of plasma FA levels
[112,113,117]. Thus, TAG/FA cycle in white adipocytes has the key role
in metabolic ﬂexibility of adipocytes, as well as the whole organism.
In fact, it has been recently suggested that FA liberated from TAG intra-
cellularly during lipolysis are released from the adipocyte and immedi-
ately taken back by fatty acid translocase/CD36 (FAT/CD36)-mediated
mechanism to impose an additional level of regulation on lipolysis
[124].
In isolated white adipocytes, the activity of TAG/FA cycle is stimu-
lated by all lipolytic agents (reviewed in [125,126]), like β-adrenergic
agonists, ACTH, TSH and glucagon, while insulin and triidothyronine
have no effect [127]. Injection of β-adrenergic agonist in mice could
increase activity of TAG/FA cycle 5-fold in parametrial WAT and
3-fold in interscapular BAT [128]. In accordance with its control by
adrenergic system activity, TAG/FA cycle is increased in response to
fasting in rats [114], while cold exposure of mice had no effect on
TAG/FA cycle activity in WAT, but increased this activity 2-fold in
the BAT [128]. Importantly, the rate of TAG/FA cycling in WAT was
also increased, when 24-hour-starved mice had eaten for 1 h, as a re-
ﬂection of increased sympathetic stimulation of the tissue under
these conditions [128].
There must be a balance between the rates of lipolysis and the gen-
eration of glycerol-3-phosphate in order to support FA re-esteriﬁcation
(see Section 2.1). Thus, under physiological conditions such as short-
term fasting, there is a striking correlation between lipolysis and FA
re-esteriﬁcation [114], while the expression and activity of PEPCK are
up-regulated to match the rate of glyceroneogenesis with that of lipol-
ysis [118,129]. Recently, both PEPCK gene expression and the content of
the enzyme in WAT have been shown to be regulated by FAT/CD36,
possibly secondary to the regulation of lipolysis [130]. In response to
long-term fasting [114] and other strong hormonal and pharmacologi-
cal stimuli, the balance between the rates of lipolysis and FA
re-esteriﬁcation within adipocytes may be affected ([116,117]; see
also below). Moreover, this balance can be shifted in transgenic mice.
Thus, overproduction of PEPCK, the key enzyme of glyceroneogenesis,
in WAT (see Section 2.2) induces obesity and insulin resistance [131,132],
while mice with adipose-speciﬁc PEPCK inactivation display
lipodystrophic features [133].
Energy required for TAG/FA cycle was estimated by Baldwin [134]
to be 8 molecules of ATP per release and re-esteriﬁcation of 3 mole-
cules of FA. This demand could by covered either by β-oxidation of
FA in mitochondria during fasting and under other circumstances
leading to the stimulation of lipolysis in WAT, or by oxidation of
glucose in fed state, but also via energy equivalents produced during
de-novo lipogenesis. Thus, the synthesis of fatty acid-CoA from
glucose is associated with a net phosphorylation of ADP—as some
NADPH, needed for the process, is generated in pentose phosphate
pathway, the amount of ADP phosphorylation linked to oxidation of
glucose to acetyl-CoA is greater than the amount of ATP hydrolyzed
during conversion of acetyl-CoA into acyl-CoA. Therefore, excessive
amounts of ATP or other reducing equivalents produced during
de-novo lipogenesis from glucose could be a rate-limiting step for
the anabolic process [121,135,136], but the surplus of energy could
be consumed by the TAG/FA cycling (ATP needed for activation of
FA into FA-CoA and reducing equivalents needed for glycerol phos-
phate generation; [121,136]).
Higher activity of TAG/FA cycle in human visceral WAT [137] corre-
sponds with relatively high mitochondrial content and OXPHOS
activity in this fat depot as compared with subcutaneous WAT (see
Section 2). Moreover, induction of lipolysis in adipocytes is linked to
stimulation of mitochondrial β-oxidation ([138]; see below). In turn,
a decrease in mitochondrial ATP production results in the inhibition
of both FA synthesis and lipolytic action of catecholamines (reviewed
in [102,139]; see also [140]). Also the transcriptional activity of
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ity is impaired by OXPHOS inhibitors [141].
In the absence of the stimulation of TAG/FA cycle, oxidation of FA
is relatively slow, which is consistent with the low CPT1 activity in
WAT [26,52]. For instance, in normal fed rats only 0.2% of endogenous
FA in white adipocytes were oxidized while 50.1% were released and
49.7% re-esteriﬁed [58]. However, the amount of FA disposed through
oxidative pathway increased about 1.5-fold with the stimulation of li-
polysis and TAG/FA cycle by fasting [58]. Based on these numbers, it
can be calculated that the amount ATP produced during β-oxidation
of FA is fully sufﬁcient to cover the energy costs of the process (not
shown). In accordance with the data from the animal studies, direct
calorimetry in human adipocytes isolated from subcutaneous WAT
revealed that FA re-esteriﬁcation contributed by 15% and 27% to
WAT thermogenesis in the absence and presence of catecholamine,
respectively [5]. Although Ball [142] has suggested that as much as
15% of basal metabolism in rats can be provided by TAG/FA cycle in
WAT, and based on extrapolation of these data he also assumed that
TAG/FA cycle could be responsible for 100% (!) of basal metabolism
in humans [142], later experiments and calculations indicated that
WAT basal metabolism in mouse, rat and dog contributed less than
1% [121]. While even the rat data seem to be unrealistically high,
the extrapolation to humans is apparently skewed by much higher
speciﬁc metabolic rate in the tissues of the smaller species [143].
Based on data published on re-esteriﬁcation in lean men fasted for
60 h [144], it could be estimated [121] that the rate of heat produc-
tion by systemic re-esteriﬁcation (liver, adipose tissue, skeletal mus-
cle) accounts for about 1.5% of basal metabolic rate, similarly as in
the animals (see above). Reﬂecting these conservative estimates, as
well as the contribution of FA re-esteriﬁcation to thermogenesis in
white adipocytes and contribution of WAT to resting metabolism in
humans ([5], see also Section 1), it is to be inferred that TAG/FA
cycle inWAT could be responsible for about 2–3% of resting metabolic
rate in moderately obese humans.
As suggested by Gauthier et al. [145], the main role of AMPK (see
Section 2.1) activation in white adipocytes could be to restrain energy
depletion and oxidative stress associated with lipolysis. Thus, it is
conceivable that AMPK plays a key role in the up-regulation of mito-
chondrial biogenesis and activation of β-oxidation of FA in mitochon-
dria under various conditions leading to stimulation of lipolysis and
TAG/FA cycle. Accordingly, activation of AMPK in white adipocytes
was observed during starvation [146], or during physical exercise
[105], which was also shown to increase activity of mitochondrial en-
zymes [147] as well as the expression of both PEPCK and PDK4 genes
in WAT [148]. Also hyperleptinemia in rats leads to the stimulation of
mitochondrial FA oxidation [149], AMPK activation and induction of
TAG/FA cycle in white adipocytes [149]. Forced expression of PGC1α
in combination with PPARα increases the activity of TAG/FA cycle in
human white adipocytes [150]. However, similarly as in the case of
leptin (see above), and all the treatments inducing brite cells
(see Section 3.1), this manipulation also resulted in the induction of
UCP1 in WAT, which makes it difﬁcult to dissect the impact of TAG/
FA cycle activation and mitochondrial uncoupling in WAT on whole-
body energy balance.
AMPK also exerts complex modulation of lipolysis in white adipo-
cytes [151–153] by regulating independently activities of the key en-
zymes involved [125], i.e. the hormone-sensitive lipase (HSL), which
catalyses the hydrolysis of TAG into diacylglycerols and diacylglycerols
into monoacylglycerols, and desnutrin/adipose triglyceride lipase
(ATGL), an enzyme catalysing the initial step in TAG hydrolysis
[154,155] and rate-limiting hydrolysis of TAG [156]. In the interplay
with HSL, which also involves protein kinase A, activation of AMPK
increases acute lipolytic response [153], while in the long term, HSL
activity is inhibited by an AMPK-mediated mechanism [152,153]. On
the other hand, AMPK-induced phosphorylation of ATGL leads to a
long-term activation of lipolysis [116,151,157]. As suggested by Langinet al. [116], diacylglycerols formed by ATGL-mediated lipolysis could
augment FA re-esteriﬁcation. Based on its inﬂuence on lipolysis,
AMPK may exert ﬁne control of TAG/FA cycle and it could modulate
the coupling between lipolysis and FA re-esteriﬁcation.
Moreover, as shown in the heart [158], probably also in adipose
tissue [159,160] ATGL-mediated lipolysis is important for the genera-
tion of ligands or precursors of ligands for nuclear receptors such as
PPARα (see Section 2.1) or PPARδ, which control the expression of
FA oxidation genes and mitochondrial OXPHOS activity [158,160], as
well as expression of UCP1 in BAT [78]. As suggested by the group
of Granneman [160], the induction of FA catabolism by this mecha-
nism in WAT is important for limiting pro-inﬂammatory signalling
during chronic lipolytic stimulation, and HSL-mediated lipolysis
could be also involved [161]. The Granneman's hypothesis could be
extended to suggest that the ATGL-dependent remodelling of WAT
is also essential for increasing the mitochondrial OXPHOS activity,
as required for covering the energy cost of the activation of TAG/FA
cycle in white adipocytes.2.4. Obesity is linked with altered mitochondrial energy metabolism in
white adipocytes
Obesity is associated with a poor performance of mitochondria in
WAT (see Section 1). However, mitochondrial function in WAT is not
impaired in lean subjects with type 2 diabetes [162]. As reviewed by
Kusminski and Scherer [163], it is conceivable that in obese state
mitochondria in WAT similarly to mitochondria in other tissues
[164] are not able to cope with increasing demands for FA oxidation,
resulting in incomplete β-oxidation, which is also associated with a
stress of endoplasmic reticulum [163,164]. Altered redox state,
which is associated with increased mitochondrial ROS formation
and accumulation of the products of incomplete β-oxidation, such
as partially oxidized acylcarnitines [165], leads to a deterioration of
insulin sensitivity [164]. In addition, high anaplerosis in WAT mito-
chondria in obesity may result in insufﬁcient oxidation of metabolites
arising from degradation of branched-chain amino acids (BCAA),
supporting further the development of systemic insulin resistance
[166,167]. Obesity may also lead to impaired detoxiﬁcation of xenobi-
otics, which is linked to oxidative metabolism in WAT [168]. Impor-
tantly, the redox imbalance in obesity [164] may promote further
lipid accumulation due to an increased supply of NADPH for FA
synthesis in white adipocytes (see Section 2.2). As mentioned above
(Section 2.1), pro-inﬂammatory signals in obese state may promote
CDK5-mediated phosphorylation of PPARγ on serine residue 273 in
white adipocytes, resulting in unfavourable changes in gene expres-
sion, including down-regulation of adiponectin [84,86]. In concert
with a down-regulation of PGC-1α [169] and increased tonus
[100,170] of endocannabinoid system [171] in obesity, the changes
in the activity of PPARγ signalling may impair mitochondrial biogen-
esis in adipocytes. In addition, mitochondrial content and function in
adipocytes in obesity could be compromised reﬂecting the impair-
ment of AMPK-SIRT1 signalling [99]. Indeed, low-grade inﬂammation
of WAT induced by HF diet feeding in mice results in proteolytic
cleavage of both PPARγ [172] and SIRT1 [173] in adipocytes, while
SIRT1 transcription was decreased in visceral WAT of obese human
patients [174].
In dietary-obese mice, but not in lean mice, pharmacological block-
age of CB1 receptors resulted in lower accumulation of body fat [175],
in accordance with the anti-obesity effect of the cannabinoid antago-
nists in humans [176] and obesity resistance of the CB1 receptor knock-
out mice [177]. Importantly, the amelioration of obesity in mice treated
with cannabinoid antagonists was associated with the induction of
mitochondria, β-oxidation, lipolysis and probably also TAG/FA cycle
in white adipocytes, while oxidative capacity of brown fat cells was
also increased [175].
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response to PPARγ activation
Mitochondrial insufﬁciency in white adipocytes of obesemice could
be normalized by the treatment with a PPARγ agonist, a TZD com-
pound rosiglitazone [10]. In addition, TZD could also activate AMPK
signalling by a rapid, PPARγ-independent mechanism [178]. TZD
supports BCAA catabolism in WAT [179], which may contribute signif-
icantly to the insulin-sensitizing effect of TZD in obesity [180]. TZD also
induces the expression of genes involved in glyceroneogenesis (see
Section 2.2), namely the genes encoding for PDK4 and PEPCK [113] as
well as glycerol kinase selectively in adipose tissue [181]. Our
unpublished results document similar up-regulation of PEPCK by TZD
in both epididymal and subcutaneous WAT, while glycerol kinase
gene was induced more in the subcutaneousWAT. Moreover, TZD sup-
port both mitochondrial anaplerosis and de novo lipogenesis in WAT
by up-regulating PC [182], as well as FA re-uptake for re-esteriﬁcation
by stimulating FAT/CD36 gene expression (see Section 2.3 and [124]).
Thus, concomitantly with the induction of mitochondrial oxidative
capacity, rosiglitazone stimulates glycerol incorporation into TAG, in-
duces futile FA re-esteriﬁcation cycle and thus reduces FA release
from adipocytes [112]. The complex modulation of adipocyte metabo-
lism by this PPARγ agonist documents further the tight link between
mitochondrial oxidative capacity (and OXPHOS) and TAG/FA cycle in
white adipocytes.
As mentioned above (see Section 2.1), activation of PPARα and
PPARγ in WAT also results in a potent anti-inﬂammatory effect. It is
to be inferred that signalling mediated by PPARs in white adipocytes
is the key element in the complex regulation of tissue metabolism
and inﬂammation, and underlies the role of WAT in the whole-body
homeostasis [92].
The TZD-induced remodelling of WAT is also associated with the
induction of UCP1 [10]. The capability to induce UCP1 in WAT in re-
sponse to TZD rosiglitazone, that is also regarded as a classical inducer
of the formation of brite cells [29], depends strongly on the anatomi-
cal location of WAT, with subcutaneous WAT showing relatively high
inducibility of the UCP1-harbouring adipocytes, while epididymal fat
is much less affected [28]. Apparently, the control of the UCP1 content
in adipocytes depends on both the speciﬁc structure of regulatory
parts of the UCP1 gene and the interplay of intracellular transcrip-
tional and translational modulators. It could be speculated that TZD
activates UCP1 gene only in brite cells but not in classical white
adipocytes. If this was the case, and UCP1 activity in brite cells is
regulated similarly as in BAT, induction of UCP1-mediated thermo-
genesis in these cells would require adrenergic stimulation [183].
However, it can be also speculated that the induction of UCP1 gene
expression by strong pharmacological agonists like TZD, which re-
ﬂects a direct interaction of PPARγ [184] with the regulatory region
of the UCP1 gene [185,186], overrides a ﬁne physiological regulation
of both UCP1 gene expression and mitochondrial biogenesis, and
could result in UCP1 synthesis in classical white adipocytes. It has
been shown that ectopic expression of UCP1 in white adipocytes
resulted in mitochondrial uncoupling [187] and increased oxygen
consumption by WAT in the absence of adrenergic stimulation [6],
while the protonophoric activity of the ectopic UCP1 in WAT mito-
chondria retained its normal control by free FA and nucleotides
[187]. Therefore, TZD-induced synthesis of UCP1 in white adipocytes
could compromise mitochondrial ATP production even in the absence
of adrenergic stimulation.
3. Modulation of metabolic ﬂuxes in white adipocytes may affect
adiposity
It is conceivable that a shift in the balance among activities of the
major metabolic pathways contributing to TAG/FA cycle in white
adipocytes, i.e. lipolysis of TAG and re-esteriﬁcation of FA, as well asin the associated metabolic ﬂuxes such as de novo FA synthesis and
mitochondrial β-oxidation, could affect cellular lipid content ([58];
see Section 2.3). Thus, in spite of the induction of mitochondrial
oxidative capacity (and even UCP1 expression in WAT in the animal
experiments; see Section 2.5), pharmacological interventions using
TZD in diabetic patients lead to redistribution of body fat, with in-
creased TAG accumulation in the subcutaneous fat depots and de-
creased accumulation of abdominal fat [188]. Conversely, fasting in
mice leads to preferential reduction of subcutaneous WAT, which
could reﬂect fat-depot-speciﬁc differences in the rate of PEPCK-
dependent FA re-esteriﬁcation [146].
3.1. Energy expenditure in WAT could compromise accumulation of
body fat
Some interventions,whichmodulatemetabolic ﬂuxes in adipocytes,
may result in a general decrease of accumulation of body fat. Most of
them, e.g. pharmacological stimulation of PPARα [78], forced lipolysis
[189,190], leptin treatment [149], or overexpression of PGC-1α
[77,191] activate the whole programme of UCP1-mediated thermogen-
esis and mitochondrial uncoupling within adipocytes, i.e. the induction
of brite cells (see Section 1). However, in most cases, the changes in
lipid accumulation in WAT are also associated with the induction of
UCP1-mediated thermogenesis in classical BAT depots (reviewed in
[192]), i.e. the process, which is probably much more relevant with
respect to changes of whole body energy metabolism.
Importantly, some interventions may limit accumulation of body
fat while inducing lipid catabolism in WAT in the absence of any
induction of UCP1. This also includes pharmacological activation of
AMPK in rats [193], which was accompanied by increased oxidation
of FA [157] and, paradoxically (see Section 2.3), decreased activity
of FA re-esteriﬁcation in adipocytes [193]. As mentioned above
(see Sections 2.1 and 2.3), AMPK is implicated in the control of activ-
ity of both TAG/FA cycle andmitochondrial biogenesis in white adipo-
cytes. Furthermore, mice with genetic disruption of UCP1 are
resistant to obesity when reared under the conditions of a mild cold
stress but not at thermoneutral temperature [194,195]. This striking
induction of obesity resistance could involve increased energy expen-
diture in WAT, as suggested by the elevated cytochrome oxidase
activity in WAT of the UCP1-ablated but not wild type mice in
response to cold exposure [196]. It could be speculated that under
conditions of increased sympathetic stimulation and increased lipoly-
sis in WAT, TAG/FA cycle could be activated and contribute to the in-
duction of energy expenditure. However, shivering [19,20], as well as
non-shivering thermogenesis in skeletal muscle (for review see
[15–17]) can be also involved in the obesity resistance of these mice.
3.2. UCP1-independent induction of energy dissipation in WAT by
combined intervention using omega 3 FA and mild calorie restriction
As we have shown recently in mice fed HF diet [27], combined
intervention using long-chain n-3 polyunsaturated FA (omega 3) and
mild calorie restriction (CR) exerted synergism in the prevention of
obesity despite no increases in physical activity. The combined inter-
vention also prevented low-grade obesity-associated inﬂammation of
WAT, exerted hypolipidemic and insulin-sensitizing effects, as well as
synergistic induction of mitochondrial OXPHOS in epididymal WAT,
which could not be detected either in other fat depots including
interscapular BAT or in non-adipose tissues. Importantly, all these met-
abolic changes occurred in the absence of any induction of UCP1 in
WAT, and they were associated with a signiﬁcant stimulation of palmi-
tate oxidation measured ex vivo in both epididymal fat fragments and
collagenase-liberated adipocytes from epididymal WAT of mice
subjected to the combined intervention. Thus, the induction of UCP1-
independent energy expenditure in WAT could be involved in the
lower accumulation of body fat.
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creased levels of UCP1 mRNA and/or protein in BAT in response to di-
etary omega 3 supplemented to a diet high in fat [197,199] or sucrose
[198], we did not observe any changes in UCP1 mRNA levels in BAT of
mice fed omega 3-supplemented diet when compared to HF-fed con-
trols [27]. Moreover, histological analysis of BAT from HF-fed mice
suggested an increased lipid deposition in the tissue, which was
unchanged by supplementing the HF diet with omega 3 (unpublished
data). It could be only speculated whether interspecies differences or,
perhaps, different dietary contents and intake of omega 3 could ex-
plain differential effects of omega 3 on UCP1 gene expression in the
above studies. That the anti-obesity effect of omega 3 in mice fed HF
diet was independent of cold-induced thermogenesis is further
supported by our recent publication [200], showing reduced accumu-
lation of body fat following a long-term feeding with omega 3-
supplemented HF diet in mice maintained at thermoneutral (30 °C)
temperature.
Omega 3, namely eicosapentaenoic acid (EPA; 20:5 n-3) and
docosahexaenoic acid (DHA; 22:6 n-3), exert hypolipidemic effects
[201,202], reduce systemic inﬂammation [203,204] as well as low-
grade inﬂammation of WAT [27,205–207] and limit hepatosteatosis
[27,207–210]. In humans, omega 3 lowers cardiovascular morbidity
and possibly also the incidence of type 2 diabetes [211–213]. Many an-
imal studies showed anti-obesity effects of omega 3 [27,66,207,
208,214], while human studies documenting lower accumulation of
body fat in response to omega 3 are scarce and they were mostly
performed in the combination with energy restricted diets [215,216].
CR without malnutrition is an essential component in the treat-
ment of obesity and associated diseases [217]. In many aspects, CR
and metabolic syndrome could be opposite extremes of the same
metabolic spectrum [218]. In organisms ranging from yeast to mam-
mals, CR prolongs life span while inducing SIRT1 and mitochondrial
SIRT3 deacetylases, which modify activity of several transcription fac-
tors, regulatory proteins and metabolic enzymes (see Sections 2.1 and
2.4 and [218,219]).
Our results suggested that the synergistic induction of FA oxida-
tion in WAT in response to the combined intervention using omega
3 and CR could be explained by the stimulation of TAG/FA cycle in
white adipocytes [27]. As documented in Fig. 1A, this idea is stronglyFig. 1. Expression of genes encoding PEPCK and FAS in WAT. A, B: Quantitative real-time RT-P
the combined intervention using omega 3 and mild CR. For experimental details see [27]. C, D
mice fed HF diet. For experimental details see [273,277]. Data are means±SE; n=7–10. In A
differences (ANOVA) compared with ad libitum HF diet supplemented or not with omega 3; csupported by additive effects of the combined intervention on the ex-
pression of PEPCK in epididymal fat. PEPCK is the rate-limiting en-
zyme in glyceroneogenesis and it is required for TAG/FA cycle in
white adipocytes (see Section 2.2). Accordingly, DHA alone could
act as an inducer of PEPCK mRNA expression (Fig. 1A and [220]),
and our recent results documented that omega 3 could induce FA
re-esteriﬁcation in epididymal WAT of mice fed a HF diet even at
the thermoneutral temperature [200]. Moreover, CR as well as fasting
stimulated the expression of PEPCK in rodents fed a low-fat chow diet
[221,222] and up-regulated the expression of lipogenic genes while
increasing the rate of FA synthesis speciﬁcally in WAT [223]. Interest-
ingly, proteome analysis in rats indicated an activation of FA synthesis
by CR in both WAT and BAT, while mitochondrial function was en-
hanced only in WAT [224].
When applied separately, both omega 3 [66] and CR [27,101,
222,224,225] induce mitochondrial biogenesis in WAT, and both
omega 3 [207,226] and CR [227] can be combined with other interven-
tions to modulate the activity of an integrated circuit of intracellular
energy sensors SIRT1 and AMPK (see Section 2.1). The induction of
mitochondrial biogenesis down-stream of AMPK and SIRT1 involves
transcription factors PPARα/γ, PGC-1α and NRF-1 (see Section 2.1
and Fig. 2).
That the combined intervention using omega 3 and CR results in a
relatively strong induction of TAG/FA cycle, mitochondrial OXPHOS ac-
tivity, and FA oxidation speciﬁcally in epididymal WAT, could reﬂect
interplay of the following factors: (i) epididymal WAT is characterised
by inherently higher mitochondrial content (see Section 2), relatively
high responsiveness of adipocytes to both insulin [228] and
β-adrenergic agonists [229], andmuch higher activation of AMPK in re-
sponse to energy deprivation as compared with subcutaneous WAT
[146]; (ii) omega 3 induce adiponectin [202,230] that may act locally
in WAT to stimulate AMPK signalling; (iii) omega 3 may normalise
the tonus of the endocannabinoid system [209,231,232], which is
dysregulated in obesity (see Section 2.4), especially through their
effects on WAT [233], hence counteracting the inhibition of AMPK by
CB1 receptor-mediated signalling (see Section 2.1); (iv) both omega
3 and CR augment lipid catabolism through the activation of PPARα
signalling ([81]; in fact, only FA released from endogenous TAG in adi-
pocytes represents the available energy substrate when food intake isCR data showing mRNA levels in epididymal fat of male mice (C57BL/6J) after 5 weeks of
: mRNA levels in epididymal fat of control non-transgenic and aP2-Ucp1 transgenic male
and B: white bars, HF diet; black bars, HF diet supplemented with omega 3. a,bSigniﬁcant
Signiﬁcant differences (t-test) compared to control mice (i.e. non-transgenic littermates).
Fig. 2. Proposed scheme of modulation of metabolic ﬂuxes in adipocytes in the epididymal WAT in response to the combined intervention using omega 3 and CR in mice fed HF diet.
As explained in the main text, the combined intervention is associated with the reduction of low-grade inﬂammation of WAT, induction of adiponectin, lowering of the tonus of the
endocannabinoid system (lower levels of major endocannabinoids in the tissue in response to omega 3 supplementation), higher adrenergic stimulation of adipocytes (elicited by
CR), and amelioration of HF diet-induced insulin resistance. Synergistic induction of the formation of lipid mediators such as 15d-PGJ2, which are derived from polyunsaturated FA
released from membrane phospholipids by phospholipase A2 (PLA2), and decreased activity of the CDK5 in response to the anti-inﬂammatory effect of the intervention lead to the
activation of PPARγ signalling and up-regulation of speciﬁc genes engaged in mitochondrial biogenesis and lipid catabolism, as well as FA synthesis and glyceroneogenesis. PPARα
and PGC-1 are also involved in the changes of the transcriptional programme in white adipocytes. The changes at the level of gene expression are reﬂected in the induction of mi-
tochondrial β-oxidation, PEPCK-dependent glyceroneogenesis, and activation of the TAG/FA cycle. De novo FA synthesis is supported by the insulin-sensitizing effect of the inter-
vention, depending possibly in large on the PPARγ activation. The induction of TAG/FA cycle (FA liberated from TAG during lipolysis may be released from the adipocyte and
immediately taken back by FAT/CD36-mediated mechanism—not shown) and activation of FA for β-oxidation requires ATP, leading to lowering of cellular energy status (i.e. an
increased AMP/ATP ratio) and activation of AMPK. At the early stages of adrenergic stimulation, the activity of AMPK is compromised by protein kinase A (PKA)-mediated inhibition
that is released at later stages of the stimulation. In addition, AMPK activity is possibly further augmented, reﬂecting a decrease in the endocannabinoid tonus. The activation of
AMPK would support the induction of mitochondrial biogenesis, OXPHOS, and β-oxidation while limiting the lipolytic response, and hence the release of FA from adipocytes.
AdipoR, adiponectin receptor; COX, cyclooxygenase; LOX, lipoxygenase.
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low-grade inﬂammation of WAT, which, in turn may prevent CDK5-
mediated phosphorylation of PPARγ, and therefore, secure a beneﬁcial
pattern of PPARγ-mediated changes in gene expression (see
Section 2.1).
The anti-inﬂammatory effects of omega 3 depend in large on the
formation of their active metabolites. These lipid mediators originate
from either targeted enzymatic synthesis, as in case of resolvins and
protectins [235,236], or from non-enzymatic oxidation reactions [234,
237]. They can act as ligands for surface receptors, namely the lipid
sensor GPR120 [206] or can interact with transcription factors like
PPARγ and NF-κB [234]. Notably, resolvins and protectins mediate
the anti-inﬂammatory and protective actions of omega 3 on obesity-
induced insulin resistance and hepatic steatosis [235,238]. As we
have shown recently [27], the combined intervention using omega 3
and CR induced 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) and
protectin D1 (PD1) with a surprising synergism observed in epididy-
mal fat, but not in the liver. The induction of these lipid mediators
could contribute to the anti-inﬂammatory effect of this intervention,
while activation of PPARγ resulting from the supposed 15d-PGJ2
binding [239,240] could impact on mitochondrial biogenesis,
glyceroneogenesis, adiponectin formation and other PPARγ-mediated
effects (see Section 2.1).As summarized in the following section, the levels of various lipid
mediators in WAT could largely depend on the presence of various
cell types in the tissue and on the changes in the pattern of formation
of these lipid mediators in response to local inﬂammatory status.
4. Role of local lipid mediators in regulation of WAT metabolism
In addition to differentiated adipocytes and their precursors, in-
nate immune cells including macrophages, mast cells, neutrophils,
or eosinophils can be found in WAT [87,88]. Among them, adipose-
tissue macrophages (ATM), major antigen-presenting cells, are func-
tionally and numerically dominant and exert both immune and
housekeeping functions. A state of chronic mild inﬂammation and dys-
function of WAT present in obesity can be linked to the inﬁltration of
pro-inﬂammatory macrophages (M1 phenotype), which produce
pro-inﬂammatory cytokines [87–89,241]. ATM in leanmice show an al-
tered, less-inﬂammatory properties (M2 phenotype; [242]). Cytokines
released from M1 macrophages block insulin action in adipocytes via
TNF-α pathway, promote extracellular matrix remodelling and ﬁbrosis
of WAT, recruit other immune cells such as mast cells, B-cells or T-cells,
and form crown-like-structures that encircle necrotic adipocytes to
phagocytose debris [243]. These sub-populations release either
anti-inﬂammatory (IL-4, IL-10, IL-13) or pro-inﬂammatory (TNF-α,
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saccharide (LPS) or palmitic acid promote M1-polarization via TLR4
pathway [245,246], and TLR antagonists including EPA or the
adiponectin paralog C1q/TNF-related protein 3 (CTRP3; [247]), an en-
dogenous LPS antagonist in adipose tissue, might be slowing down
the inﬂammation. All these mediators affect also adipocytes, which
themselves produce all kinds of adipokines with pro- or anti-
inﬂammatory properties (monocyte chemoattractant protein-1,
MCP-1; resistin, adiponectin, etc.; [87]). Importantly, reduction of
WAT expression of SIRT1 in obesity (see Section 2.4) is causally linked
to the macrophage inﬁltration [96]. Recent hypothesis on WAT inﬂam-
mation proposes that the M1 response increases fuel demand for ster-
ile immune response, thus increasing hyperglycaemia and lipolysis to
supply nutrients for activated immune cells, while the M2 response
suppresses the clonal expansion of Th1 cells and enhance nutrient stor-
age by potentiating the action of insulin [248].
Besides the cytokines, a large family of endogenous lipid mediators
derivedmainly from arachidonic acid (AA; 22:4 n-6), contributes to theTable 1
Lipid mediators and intercellular signalling in WAT.
Model Species Tissue Lipid mediator Source o
mediator
Adipocytes, SVF Human Subcutaneous PGE2 Endo
Adipocytes, SVF Rat PGE2, PGI2 Endo+e
Adipocytes, SVF,
3T3-L1
Mouse Epididymal PGE2, PGI2 Endo
Adipose tissue,
adipocytes




Mouse Intra-abdominal cPGI2, PGE2,
PGI2
Exo+en
Adipocytes, SVF, BAT Mouse Inguinal PGE2 Exo
BAT Mouse Interscapular PGE2 Exo




3T3-L1 PGJ2 series Endo












Rat Perigonadal 12-HETE, 5-HETE,
LTB4
Exo





Mouse Visceral EET, DHET mix Exo
Adipocytes, SVF,
macrophage
Mouse Epididymal RvD1 Endo+e
Adipose tissue,
SVF
Mouse Epididymal RvD1 Exo
Adipose tissue Mouse Epididymal 17-HDHA, PD1,
RvD1
Exo





Human, mouse Epididymal RvD1, RvD2 Exo
Adipose tissue Mouse Epididymal PD1, d15-PGJ2 Endo
Adipose
tissue/leukocytes
Mouse Perinodal RvE1, PD1, LXA4 Exo





Mouse Perigonadal LXA4 Exo
Adipocytes, collagenase-liberated adipocytes from adipose tissue; SVF, stromal vascular fra
mediator (produced by the tissue itself); exo, exogenous application of the mediator (artiﬁinﬂammatory state in WAT [244]. As mentioned above (see
Sections 2.1, 2.4, and 3.2), endocannabinoids deteriorate AMPK signal-
ling in WAT, and omega 3 supplementation results in lowering of their
tissue levels, reﬂecting the replacement of AA in membrane phospho-
lipids by DHA and EPA. Eicosanoids, products of cyclooxygenases,
lipoxygenases, and cytochromes P450, are potent local mediators of
signal transduction and modulate the inﬂammatory response.
Although immune cells are the main producers of eicosanoids, also ad-
ipocytes synthetize prostanoids (PGE2, PGI2, PGF2α) and leukotrienes
and express eicosanoid receptors. Thus, members of both adipocyte
and immune cell lineages are able to communicate using lipid media-
tors as membrane or nuclear receptor ligands. Selected lipid mediators
produced in adipose tissue are summarized in Table 1. Prostanoids are
important for differentiation of adipocytes, and can regulate lipolysis in
an autocrine and paracrine manner through PGE2 or even shift the
differentiation of deﬁned mesenchymal progenitors toward a brown
adipocyte phenotype. PGE2 was shown to induce UCP1 in white
adipocytes and stimulate thermogenesis in BAT. Cyclopentenonef Effect Reference
Modulation of adipogenesis [279]
xo Modulation of lipolysis [280]
Modulation of lipolysis [190]
Stimulation of leptin release [281]
Modulation of adipogenesis [282]
do Shift the differentiation of mesenchymal progenitors toward a
brown adipocyte phenotype, induction of UCP1 in WAT
[254,255]
Induction of UCP1 in white adipocytes, no effect in BAT [254]
Stimulation of thermogenesis in BAT [283]
Regulation of BAT substrate utilisation, modulation of lipolysis [256]
Increase of glucose transport [284]
Modulation of adipogenesis and MCP-1 expression [285]
Production of macrophage inhibitory cytokine-1 [286]
Decrease of leptin production [287]
Stimulation of adipogenesis [239]
Promotes adipocyte differentiation [240]
Secretion of MCP-1, IL-6, and TNF-a [288]
Chemoattractant for macrophages in obesity [289]
Upregulation of IL-6, TNF-alpha, MCP-1 [290]
xo Induction of ER stress [291]
Modulation of adipocyte differentiation, decreased TNF-alpha,
MCP-1, increase of adiponectin
[292]
xo Downregulation IL-6, MCP-1, and TNF-a, ROS; upregulation of IL-10,
CD206, arginase 1, resistin-like molecule a, and chitinase-3 like
protein, stimulated nonphlogistic phagocytosis; shift M1>M2
macrophage phenotype
[249]
Increase of adiponectin production and insulin sensitivity; decrease
of IL-6 production and macrophage inﬁltration; shift M1>M2
macrophage phenotype
[293]
Increase of adiponectin and insulin sensitivity [235]
Prevention of obesity-linked inﬂammation and insulin resistance [236]
Increase of adiponectin; decrease of leptin, TNF-a, MCP-1, IL-6, and
IL-1b
[253]
Induction of lipid catabolism, antiinﬂammatory [27]
Resolution of inﬂammation [294]
Modulation of inﬂammatory status in adipose tissue [295]
Decrease of IL-6 and increase of IL-10 expression; increase of insulin
sensitivity, antiinﬂammatory
[296]
ction from adipose tissue (containing immune cells); endo, endogenous source of the
cial stimulation).
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transcription of genes (see Section 2.1), including those involved in
the production of adipokines linked to inﬂammation. Both PGE2 and
15d-PGJ2 are synthetized within cyclooxygenase pathway, but in dif-
ferent branches using either prostaglandin E or D synthases, potentially
leading to either pro- or anti-inﬂammatory mediators. The possibility
of modulation of these synthases adds another layer of complexity. Dis-
covery of pro-resolving and anti-inﬂammatory omega 3-derived lipid
mediators called resolvins (E-resolvins and D-resolvins), protectins,
and maresins opened a new ﬁeld concerning the mechanisms involved
in resolution of WAT inﬂammation [236,249,250].
In this context, our ﬁnding (see Section 3.2) of the synergistic in-
duction in WAT of speciﬁc lipid mediators, namely 15d-PGJ2 and
PD1 (or its isomer PDX with the 11E, 13Z, 15E geometry instead of
11E, 13E, and 15Z in PD1), by a combined intervention using omega
3 and CR is of utmost importance. The observed induction of
15d-PGJ2, a metabolite derived from AA (omega 6 FA), is consistent
with the results of another study [251] showing a similar induction
of 15d-PGJ2 by dietary DHA, as well as with a non-enzymatic mecha-
nism of its synthesis (see Section 3.2 and [27,251]). These results
clearly demonstrate that dietary interventions can be used to increase
local levels of lipid mediators in WAT, which can help to resolve in-
ﬂammation [252] and even modulate metabolic properties of adipo-
cytes by interacting with the major transcriptional regulatory
pathways including PPARs (see Sections 2.1 and 2.5). In fact, changes
in the levels of these types of lipid mediators may exert stronger ef-
fects than those exerted by pharmacological treatments. Thus, e.g.,
resolvins RvD1 and RvD2 counteract both local adipokine production
and monocyte accumulation in inﬂamed WAT with a 300-fold higher
efﬁciency as compared with rosiglitazone [253].
With respect to the induction of brite cells and UCP1 by PGE2
[254,255], and the induction of energy-dissipating adipocytes by
15d-PGJ2 and PD1 in response to the combined intervention with
omega 3 and CR [27], it is unclear whether these lipid mediators
could affect the same signalling pathway. PGE2 stimulated adipocytes
through EP4 receptors on the plasma membrane while 15d-PGJ2,
generated inside the cells, acted probably as a PPARγ ligand (see
Section 2.1). Also a precise role of enzymes involved in PGE2, PGD2
and PGF2α metabolism has to be further explored [256–260]. A de-
tailed characterisation of lipid mediators involved in the induction
of energy expenditure in adipocytes may contribute to better charac-
terisation of the (distinct) adipocyte cell lineage(s) involved. It could
help to clarify, whether adipocytes, in which energy expenditure is
activated through TGA/FA cycling, belong to the brite cell lineage or
whether typical white adipocytes are involved.
It has been demonstrated that obesity-associated macrophage inﬁl-
tration of WAT in mice is one order of magnitude higher in epididymal
as compared with subcutaneous WAT, and that this inﬂammatory re-
sponse is much lower in female as compared with male mice. Further-
more, female mice showed a relatively weak link between adipocyte
hypertrophy and various phenotypes such as impaired glucose homeo-
stasis and hepatosteatosis induced by HF feeding [261]. Accordingly,
the obesity-associated WAT inﬂammation resulted in mitochondrial
dysfunction in epididymal but not in periovarian WAT in the rat
[262]. Therefore, it has to be learned how mouse strain-, fat depot-
and gender-speciﬁc differences in macrophage inﬁltration of WAT
could affect metabolism of adipocytes.
In addition to various cytokines and lipid mediators, M2 macro-
phages have been recently shown to produce catecholamines in ani-
mals exposed to cold, with a straightforward implication for the
control of energy metabolism and thermogenesis in adipocytes [263].
That also adipocytes and cells within stromal vascular fraction could
serve as a source of catecholamines has been recently observed
[264,265].
It can be expected that the cell–cell interactions mediated by lipid
mediators will be affected, reﬂecting not only the low-gradeinﬂammation associated with obesity, but also changes in the im-
mune cell population in WAT, which could be associated with cancer
and, therefore, impact on metabolism of adipocytes and adiposity.
Although no direct evidence linking inﬂammation, lipid mediators,
cancer, and WAT is known, results on adipose-related breast cancer
and adipocytes show that especially PGE2, its receptors, and
cyclooxygenase-2 pathway are involved in increased aromatase acti-
vation leading to carcinogenesis [266–269]. On the contrary, growth
of breast cancer cells was decreased by omega 3 when incorporated
in plasma membranes, thus creating a pool for the synthesis of
anti-inﬂammatory mediators [270].
5. Testing the impact of increased lipid catabolism in white
adipocytes—mitochondrial uncoupling induced by transgenic
expression of UCP1
As described above (see Sections 3.1 and 3.2), mitochondrial
oxidative capacity in white adipocytes could be augmented, in the
absence of any changes in the UCP1 levels, e.g. by cold acclimation
in UCP1-ablated mice, or more physiologically, in response to the
combined intervention using omega 3 and CR. This combined inter-
vention induced a signiﬁcant increase of FA oxidation inWAT. A ques-
tion remains, however, how important the induction of energy
dissipation in bona ﬁde white adipocytes could be with respect to
the regulation of body fat stores. Useful information can be drawn
from the phenotype of transgenic mice expressing UCP1 gene from
the aP2 gene promoter, with an enhanced expression of UCP1 in
BAT and ectopic expression of UCP1 in WAT (aP2-Ucp1 mice; Ref.
[25]). These mice are resistant to obesity while showing a modulation
of various aspects of WAT metabolism as well as whole-body meta-
bolic responses (see below; for review see [93]). Since UCP1
over-expression in BAT of the aP2-Ucp1 mice results in BAT atrophy
and the impairment of BAT thermogenic functions [6,271], presum-
ably due to a toxic effect of excessive amounts of UCP1, the obesity re-
sistant phenotype of these mice likely results from uncoupled
mitochondrial respiration solely in mature white adipocytes.
5.1. Induction of mitochondrial oxidative capacity in WAT in different
models
Even the hemizygous aP2-Ucp1 transgenic mice are strongly
protected against obesity when crossed with genetically obese Avy
mice or when fed a HF diet [25,272]. In agreement with a higher
expression of transgenic UCP1 in subcutaneous as compared with
gonadal WAT [65], the transgene-induced metabolic changes were
more pronounced in the former fat depot, which also preferentially
decreased its size [25,272]. Thus, in the subcutaneous WAT of the
aP2-Ucp1 transgenic mice, 1.6-fold higher mitochondrial content
was found as compared with wild-type mice [65], in association
with a 3-fold increase in FA oxidation [273] and a 1.5-fold increase
in oxygen consumption ([6]; as measured ex vivo in epididymal
WAT).
In the UCP1-ablated mice, short-term cold exposure resulted in a
2- and 3.6-fold increase in speciﬁc cytochrome oxidase activity
(adjusted to protein content of tissue homogenates used for the mea-
surements) detected in epididymal and subcutaneous inguinal WAT,
respectively [196]. Furthermore, in epididymal WAT of inbred,
wild-type C57BL/6J mice, the intervention using omega 3 combined
with CR increased speciﬁc cytochrome oxidase activity 1.3-fold,
while the speciﬁc content of mitochondrial cytochromes as well as
palmitate oxidation adjusted to tissue weight increased 1.6-fold.
Moreover, both mitochondrial respiratory capacity and OXPHOS ac-
tivity in digitonine-permeabilised adipocytes from epididymal WAT
of mice subjected to the combined intervention were 2-fold higher
as compared with the control non-treated group, while mitochondria
in both groups of mice were highly coupled [27].
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sociated with a similar induction of mitochondrial oxidative capacity
and activity of FA oxidation in WAT and/or white adipocytes. At the
same time, up-regulation of mitochondrial oxidative capacity was rela-
tively high in WAT as compared with skeletal muscle or BAT [27,196].
Importantly, all these experiments (except for those with aP2-Ucp1
transgene transferred to the genetically obese Avy mice; Ref. [25])
were performed inmice having the same C57BL/6J genetic background.
It is to be inferred that the induction of FA oxidation in white adipo-
cytes of mice either using genetic manipulations to induce mitochon-
drial uncoupling or by activating the TAG/FA cycle (or perhaps also
by other physiological mechanisms independent of UCP1) could
contribute to obesity resistance.
5.2. Ectopic expression of UCP1 in white adipocytes as a model of brite
cells
Since cellular physiology and metabolic properties of UCP1-
containing adipocytes in WAT of the aP2-Ucp1 transgenic mice have
been already well characterised (see below), the results obtained
with this transgenic model could serve as a lead to understand the
physiology of brite adipocytes. In fact, studies of speciﬁc metabolic
features of brite adipocytes are at their beginnings, and they are com-
plicated by problems regarding the isolation of a homogenous cell
population in sufﬁcient quantities that are required for biochemical
studies. Some of the consequences arising from the ectopic expres-
sion of UCP1 in white adipocytes, which could be of interest with
respect to understanding the function of brite adipocytes, are summa-
rized below.
Ectopic UCP1 lowered mitochondrial membrane potential in adi-
pocytes isolated from gonadal fat of aP2-Ucp1 mice and rendered it
sensitive to FA and purine nucleotides. Full uncoupling activity was
achieved in the presence of ~15-fold less UCP1 than in BAT mitochon-
dria, resulting in the molar UCP1/respiratory chain ratio ~1, while this
ratio is between 5 and 11 in BAT [187]. These results document that
ectopic UCP1 was inserted correctly into the inner mitochondrial
membrane, and that a relatively very low amount of UCP1 is sufﬁcient
for a full release of mitochondrial respiratory control. These data are
also consistent with the original results of Lin and Klingenberg
[274], suggesting that the protonophoric activity of UCP1 exceeds
several-fold the proton-pumping activity of the respiratory chain in
the native mitochondrial membrane. Furthermore, despite a decline
in the content of transgenic UCP1 in WAT during ageing of the
aP2-Ucp1 mice [65], the robust anti-obesity effect of transgenic
UCP1 was observed both in the aged Avy mice expressing aP2-Ucp1
transgene (3) and in the aP2-Ucp1 mice fed HF diet during the
whole life (our unpublished results). These results suggest that
indeed even minute changes in the expression of UCP1 in WAT, as
could be the case of the induction of brite adipocytes, may have
signiﬁcant impact on the respiratory control in mitochondria in
these adipocytes. With respect to possible metabolic consequences
of the induction of brite adipocytes, which takes place preferentially
in subcutaneous WAT [28], it is important to note that the ectopic
expression of UCP1 in the transgenic mice is also much stronger in
subcutaneous as compared with gonadal WAT [65].
6. Key role of AMPK in the metabolic effects associated with the
induction of energy expenditure in adipocytes
It is striking that very different mechanisms of the induction of
energy expenditure triggered in white adipocytes in vivo, either by
the combined intervention using omega 3 and CR or transgenic
expression of UCP1, could elicit similar systemic effects, namely the
protection against obesity [25,27,272] and hypolipidemic effects
[27,275]. With respect to improvement of glucose homeostasis, the
combined intervention may be even more efﬁcient [27,272]. It canbe speculated that the cellular energy sensor AMPK in adipocytes
plays the key unifying role in these metabolic responses (Fig. 3).
Thus, in case of the combined intervention, AMPK could be activated
in response to increased demands for ATP, reﬂecting both the induc-
tion of FA re-esteriﬁcation and de novo FA synthesis. Accordingly,
starvation [146], omega 3 [226] and PPARγ agonists [178] could
stimulate AMPK activity in WAT. However, in the case of combined
intervention, the involvement of AMPK remains to be conﬁrmed
experimentally. On the other hand, in the aP2-Ucp1 mice, the activa-
tion of AMPK [273] associated with a signiﬁcant decrease of cellular
energy status in WAT [273,276] has been unequivocally demon-
strated. Thus, the activation of AMPK in response to mitochondrial
uncoupling could explain fat depot-speciﬁc depression of lipogenesis
[277] and lipolysis [276], as well as the increases in FA oxidation [273]
and mitochondrial content [65]. Indeed, an elevated activity of α1
subunit of AMPK [273], a dominant catalytic subunit in adipose tissue
[93], was detected in WAT (and especially in subcutaneous WAT) of
the aP2-Ucp1 mice. In analogy with its effects in the heart [94],
AMPK activation could also explain the induction of LPL [275]. There-
fore, it seems likely that AMPK represents the major regulatory intra-
cellular pathway responsible for the wide spectrum of effects induced
by transgenic UCP1 in white adipocytes, while at the same time the
activation of FA oxidation and inhibition of lipogenesis in response
to AMPK activation triggered by mitochondrial uncoupling would re-
duce fat accumulation.
Compared with the modulation of WAT metabolism by the
transgene-induced mitochondrial uncoupling, which could be
explained in full by the AMPK activation, the mechanistic basis of
the metabolic effects of the combined intervention with omega 3
and CR in adipocytes is more complex (see Section 3.2 and the legend
to Fig. 2). These mechanisms could explain some of the differences
between the combined intervention and ectopic UCP1 regarding
their effects on WAT and its secretory functions. For instance, PEPCK
and FAS genes in epididymal WAT are up-regulated in response to
the combined intervention (Fig. 1A,B), and it is conceivable that
PPARγ-signalling is activated in WAT of mice subjected to this inter-
vention due to both a synergistic induction of the endogenous
PPARγ activator 15d-PGJ2 and the anti-inﬂammatory effects of
omega 3 (Fig. 2). This is reﬂected by the induction of adiponectin
[27] and could be critical for improving whole-body insulin sensitivi-
ty [88]. In contrast, a down-regulation of PPARγ and its target genes
aP2 [273], PEPCK (Fig. 1C), and adiponectin (our unpublished results)
has been observed in the aP2-Ucp1 mice. Also the expression of FAS
has been down-regulated in response to mitochondrial uncoupling
(Fig. 1D and [277]). In addition, down-regulation of PC, another
PPARγ target [182], together with decreased mitochondrial ATP pro-
duction may augment the AMPK-mediated inhibition of de novo FA
synthesis in WAT of the aP2-Ucp1 mice.
It is to be stressed that under both conditions, i.e. in response to
the combined intervention and mitochondrial uncoupling in WAT,
activation of AMPK could support the metabolic effects as well as the
induction of energy expenditure by augmenting the oxidative capacity
in WAT. However, activation of AMPK alone, without concomitant
activation of futile substrate cycling or mitochondrial uncoupling, re-
spectively, for thermodynamic reasons, could not lead to any increase
in energy expenditure [93,278]. In any case, independent of energy
expenditure, AMPK-mediated activation of FA oxidation in adipo-
cytes in obesity (even at the expense of decreased glucose oxidation)
could help to counteract adipose tissue inﬂammation, as well as
lipotoxicity resulting from excessive accumulation of fat in other
tissues.
7. Conclusions, future research and new therapeutic strategies
In face of the renewed interest in mitochondrial uncoupling and the
induction of UCP1-mediated thermogenesis in adipose tissue as
Fig. 3. Putative involvement of AMPK in white adipocytes in the metabolic effects either elicited by the combined intervention using omega 3 and CR or by mitochondrial
uncoupling in the aP2-Ucp1 transgenic mice. For further details, see the main text and Fig. 2.
997P. Flachs et al. / Biochimica et Biophysica Acta 1831 (2013) 986–1003potential therapeutic tools for obesity, increasing energy expenditure
in WAT independently of UCP1 should be also considered. As demon-
strated in mice, combined intervention based on the use of speciﬁc
micronutrients, e.g. omega 3, and very mild CR could result in additive
increases of FA oxidation in WAT, which is based on the activation of
TAG/FA cycle and synergistic anti-inﬂammatory effects of the interven-
tion. The mechanistic aspects of such changes in the phenotype of
adipocytes should be further studied. That the above metabolic effects
were observed in the epididymal but not subcutaneousWAT depot sug-
gests an involvement of bona ﬁde white adipocytes rather than newly
differentiated cells belonging to another cell lineage, e.g. the one that
gives rise to brite adipocytes. Further studies in this respect should be
performed in order to characterise the expression of cell lineagemarkers
in the cells with augmented UCP1-independent thermogenesis.
In spite of the widely neglected contribution of WAT to whole-
body energy metabolism, previous studies in mice with ectopic
expression of UCP1 in WAT support the notion that modulation
of WAT metabolism could contribute to reduction of adiposity. The
comparison of phenotypic changes observed in adipocytes from
epididymal fat of mice subjected to the combined intervention with
those seen in the transgenic mice strongly suggests that by combining
physiological stimuli it should be possible to modify metabolic
properties of white adipocytes to the extent that would elicit system-
ic effects. As compared with the induction of energy expenditure by
the robust transgenic modiﬁcation resulting in mitochondrial
uncoupling, physiological modiﬁcations based on the combined inter-
vention using omega 3 and CR may have additional health beneﬁts,
namely those, which are linked to the anti-inﬂammatory effects and
to the suppression of the endocannabinoid system activity. With re-
spect to the insulin-sensitizing effect of the combined intervention,
the induction of adiponectin and stimulation of PPARγ signalling in
WAT may be important for glucose homeostasis at the whole body
level, reﬂecting the key role of PPARγ signalling in adipocytes for in-
sulin sensitivity of the organism. High capacity of mitochondrial
OXPHOS linked to inducible TAG/FA cycling activity is essential formetabolic ﬂexibility of WAT and represent the markers of healthy
adipocytes.
In this review, we better characterised the intracellular handles,
which could be targeted to improve metabolic properties of adipo-
cytes in WAT. With respect to novel therapeutic strategies, it remains
to be established whether the mechanism triggered by the combined
intervention, which modulates metabolic ﬂuxes speciﬁcally in epidid-
ymal WAT of mice, could be also elicited in human WAT. This may be
possible given a relatively high mitochondrial content and pro-
nounced activity of the TAG/FA cycle in visceral fat. New combination
treatment strategies may be designed including naturally occurring
micronutrients like omega 3 and plant polyphenols, reduced calorie in-
take, and pharmacological modulators of key signalling pathways in fat
cells. Involvement of the mutual interactions between adipocytes and
immune cells contained in WAT may be essential for the induction of
lipid catabolism in white adipocytes and the lean phenotype.Acknowledgements
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